Suppressing Halide Segregation via Pyridine-Derivative Isomers Enables Efficient 1.68 eV Bandgap Perovskite Solar Cells.

Light-induced phase segregation is one of the main issues restricting the efficiency and stability of wide-bandgap perovskite solar cells (WBG PSCs). Small organic molecules with abundant functional groups can passivate various defects, and therefore suppress the ionic migration channels for phase segregation. Herein, a series of pyridine-derivative isomers containing amino and carboxyl are applied to modify the perovskite surface. The amino, carboxyl, and N-terminal of pyridine in all of these molecules can interact with undercoordinated Pb2+ through coordination bonds and suppress halide ions migration via hydrogen bonding. Among them, the 5-amino-3-pyridine carboxyl acid (APA-3) treated devices win the champion performance, enabling an efficiency of 22.35% (certified 22.17%) using the 1.68 eV perovskite, which represents one of the highest values for WBG-PSCs. This is believed to be due to the more symmetric spatial distribution of the three functional groups of APA-3, which provides a better passivation effect independent of the molecular arrangement orientation. Therefore, the APA-3 passivated perovskite shows the slightest halide segregation, the lowest defect density, and the least nonradiative recombination. Moreover, the APA-3 passivated device retains 90% of the initial efficiency after 985 h of operation at the maximum power point, representing the robust durability of WBG-PSCs under working conditions.

Dissolved-Cl2 triggered redox reaction enables high-performance perovskite solar cells.

Constructing 2D/3D perovskite heterojunctions is effective for the surface passivation of perovskite solar cells (PSCs). However, previous reports that studying perovskite post-treatment only physically deposits 2D perovskite on the 3D perovskite, and the bulk 3D perovskite remains defective. Herein, we propose Cl2-dissolved chloroform as a multifunctional solvent for concurrently constructing 2D/3D perovskite heterojunction and inducing the secondary growth of the bulk grains. The mechanism of how Cl2 affects the performance of PSCs is clarified. Specifically, the dissolved Cl2 reacts with the 3D perovskite, leading to Cl/I ionic exchange and Ostwald ripening of the bulk grains. The generated Cl- further diffuses to passivate the bulk crystal and buried interface of PSCs. Hexylammonium bromide dissolved in the solvent reacts with the residual PbI2 to form 2D/3D heterojunctions on the surface. As a result, we achieved high-performance PSCs with a champion efficiency of 24.21% and substantially improved thermal, ambient, and operational stability.

Ion-Diffusion Management Enables All-Interface Defect Passivation of Perovskite Solar Cells.

Perovskite solar cells (PSCs) have demonstrated over 25% power conversion efficiency (PCE) via efficient surface passivation. Unfortunately, state-of-the-art perovskite post-treatment strategies can solely heal the top interface defects. Herein, an ion-diffusion management strategy is proposed to concurrently modulate the top interfaces, buried interfaces, and bulk interfaces (i.e., grain boundaries) of perovskite film, enabling all-interface defect passivation. Specifically, this method is enabled by applying double interactive salts of octylammonium iodide (OAI) and guanidinium chloride (GACl) onto the 3D perovskite surface. It is revealed that the hydrogen-bonding interaction between OA+ and GA+ decelerates the OA+ diffusion and therefore forms a dimensionally broadened 2D capping layer. Additionally, the diffusion of GA+ and Cl- determines the composition of the bulk and buried interface of PSCs. As a result, n-inter-i-inter-p, i.e., five-layer structured PSCs can be obtained with a champion PCE of 25.43% (certified 24.4%). This approach also enables the substantially improved operational stability of perovskite solar cells.

Efficient Semi-Transparent Wide-Bandgap Perovskite Solar Cells Enabled by Pure-Chloride 2D-Perovskite Passivation.

Wide-bandgap (WBG) perovskite solar cells suffer from severe non-radiative recombination and exhibit relatively large open-circuit voltage (VOC) deficits, limiting their photovoltaic performance. Here, we address these issues by in-situ forming a well-defined 2D perovskite (PMA)2PbCl4 (phenmethylammonium is referred to as PMA) passivation layer on top of the WBG active layer. The 2D layer with highly pure dimensionality and halide components is realized by intentionally tailoring the side-chain substituent at the aryl ring of the post-treatment reagent. First-principle calculation and single-crystal X-ray diffraction results reveal that weak intermolecular interactions between bulky PMA cations and relatively low cation-halide hydrogen bonding strength are crucial in forming the well-defined 2D phase. The (PMA)2PbCl4 forms improved type-I energy level alignment with the WBG perovskite, reducing the electron recombination at the perovskite/hole-transport-layer interface. Applying this strategy in fabricating semi-transparent WBG perovskite solar cells (indium tin oxide as the back electrode), the VOC deficits can be reduced to 0.49 V, comparable with the reported state-of-the-art WBG perovskite solar cells using metal electrodes. Consequently, we obtain hysteresis-free 18.60%-efficient WBG perovskite solar cells with a high VOC of 1.23 V.

[Expression profile of TGF-ß1 and BMP-7 in serum of preterm infants with respiratory distress syndrome].

OBJECTIVE: To study the expression profile and significance of serum transforming growth factor-beta 1 (TGF-ß1) and bone morphogenetic protein-7 (BMP-7) in preterm infants with respiratory distress syndrome (RDS). METHODS: Thirty-two preterm infants with RDS who were given pulmonary surfactant (PS) within 12 hours after birth were enrolled as the PS group. Twenty-eight preterm infants with RDS who were not given PS were selected as the non-PS group. Another 30 preterm infants without RDS were used as the control group. Serum levels of TGF-ß1 and BMP-7 in the three groups were measured using enzyme-linked immunosorbent assay at 0, 1, 3, and 7 days after birth. RESULTS: The PS group had higher serum levels of TGF-ß1 than the control group at 1 and 3 days after birth (P<0.05). The non-PS group had significantly higher serum levels of TGF-ß1 than the control group at 1, 3, and 7 days after birth (P<0.05), and serum levels of TGF-ß1 in the non-PS group were significantly higher than the PS group at 3 and 7 days after birth (P<0.05). The PS group had higher serum levels of BMP-7 than the control group at 1 and 3 days after birth (P<0.05). The non-PS group had higher serum levels of BMP-7 than the control group at 1, 3, and 7 days after birth (P<0.05). The levels of BMP-7 in the non-PS group at 7 days after birth were reduced than before, but were still higher than in the PS group (P<0.05). CONCLUSIONS: Both serum TGF-ß1 and BMP-7 levels increase in the early stage in preterm infants with RDS, however, in the late stage, the expression of BMP-7 decreases with the increase in TGF-ß1 expression, suggesting that administration of exogenous BMP-7 may reduce the expression of TGF-ß1, which might be a therapeutic approach for RDS in preterm infants.